ADK-17: preclinical safety of a dimethylaminoethanol derivative
E. B. Shustov, A. E. Kim · 2023 · Journal Biomed. 2023;19(3):82–86
Reported findings and study design
Preclinical safety observations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Assessed immune and reproductive endpoints | No adverse changes were reported under the tested conditions. |
This does not establish human safety or therapeutic immune suppression.
Source for the extracted data ↗ · Checked 2026-11-06
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Selected negative animal tests do not establish human safety, pregnancy safety or absence of rare toxicity.
- Preserved immune responses are not evidence of treating autoimmune disease.
- This DMAE-derived candidate must not be substituted for the diethylaminoethanol candidate FDES.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Publisher-deposited abstract and indexed original PDF passages
Review depth: Abstract checked; full PDF not retrieved
Source access and review scope
Publisher abstract; animal safety endpoints, not human exposure.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Original preclinical safety research
Citation and original source
Original source: E. B. Shustov, A. E. Kim. ADK-17: preclinical safety of a dimethylaminoethanol derivative Journal Biomed. 2023;19(3):82–86 2023.
Molekul research summary: https://molekul.io/research/shustov-adk17-safety-2023. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry